The Pacific Heart, Lung & Blood Institute
The Pacific Heart, Lung & Blood Institute
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for The Pacific Heart, Lung & Blood Institute? Learn more here.
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.
About this organization
Mission
Established in 2002, the vision of The Pacific Heart, Lung & Blood Institute (PHLBI) is to rapidly develop innovative ideas into effective cancer therapies. The mission of PHLBI is to generate hope through research, support, and education. PHLBI conducts this important work at its in-house research lab in Los Angeles and its supporting laboratory The Punch Lab at UCLA. It is the only nonprofit in the United States to conduct in-house research on mesothelioma.
About
THE PACIFIC HEART, LUNG & BLOOD INSTITUTE (PHLBI) FOCUSES ON ORPHAN DISEASES OF THE HEART, LUNG AND BLOOD THAT RECEIVE LITTLE ATTENTION AND FUNDING. ONE OF THE DIVISIONS OF PHLBI, THE PACIFIC MESOTHELIOMA CENTER (PMC), IS CURRENTLY DEVELOPING CANCER THERAPIES USING MESENCHYMAL STEM CELLS (MSCS) DERIVED FROM PLACENTA AND BONE MARROW. THESE CELLS ARE MODIFIED TO EXPRESS LARGE AMOUNTS OF INTERLEUKIN 12, WHICH STIMULATES THE IMMUNE SYSTEM TO REJECT CANCER CELLS. WE WERE AWARDED WITH OUR MESENCHYMAL STEM CELL PROJECT IN 2018.OUR TWO WORLD-CLASS RESEARCH SCIENTISTS, DR. MASAHIDE TONE AND DR. YUKIKO TONE CONTINUE THEIR IMPORTANT INVESTIGATIVE RESEARCH. MASAHIDE TONE WHO RECEIVED HIS PHD AT TOHOKU UNIVERSITY IN JAPAN AND HIS WIFE YUKIKO TONE RECEIVED HER DSC AT TOKYO METROPOLITAN UNIVERSITY IN JAPAN. BOTH SCIENTISTS HAVE WORKED AT THE UNIVERSITIES OF CAMBRIDGE AND OXFORD IN THE UK, AND THE UNIVERSITY OF PENNSYLVANIA AND CEDARS SINAI MEDICAL CENTER IN LOS ANGELES. THEY CONTINUE TO COLLABORATE WITH OUR SCIENTIFIC ADVISOR, DR. ROBERT B. CAMERON, MD, FACS, WHO IS PROFESSOR OF THORACIC SURGERY, SURGICAL ONCOLOGY AT UCLA, DIRECTOR OF THE UCLA MESOTHELIOMA COMPREHENSIVE RESEARCH PROGRAM AT THE DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA, AND CHIEF OF THORACIC SURGERY AT THE WEST LOS ANGELES VETERANS' ADMINISTRATION. A PROJECT FOR THE CLINICAL TRIAL OF IL-4-IMMUNO-TOXIN (IL-4R) MESOTHELIOMA THERAPY, PRIMARILY DEVELOPED BY THE CAMERON TEAM, HAS FOUND THAT MESOTHELIOMA EXPRESSES IL-4R AT HIGH LEVELS, AND A RECENT STUDY ALSO SUGGESTS THAT IL-4R EXPRESSION LEVELS IN MESOTHELIOMA ARE SIGNIFICANT TO SURVIVAL RATES.A STRENGTH IN OUR INSTITUTE IS THAT THE CLINICAL AND RESEARCH TEAMS ARE DIRECTLY CONNECTED, ALLOWING US ACCESS TO PATIENT SPECIMENS FOR OUR TISSUE BANK, WHICH IS THE BEST ENVIRONMENT IN WHICH TO DEVELOP CANCER IMMUNOTHERAPY STRATEGIES. THIS POSITIONS US FAVORABLY OVER OTHER RESEARCH INSTITUTIONS FOR RESEARCH BREAKTHROUGHS. ESTABLISHING NEW THERAPEUTIC STRATEGIES IS OUR HIGHEST PRIORITY.WE ARE ALSO PROUD TO CONTINUE SUPPORTING OUR INTERNATIONAL SYMPOSIUMS ON MALIGNANT PLEURAL MESOTHELIOMA. THE SYMPOSIUMS GIVE UNRIVALED OPPORTUNITIES BOTH TO THE MEDICALLY SAVVY AND TO THE GENERAL PUBLIC, INCLUDING MESOTHELIOMA PATIENTS, TO NOT ONLY LEARN FIRST-HAND ABOUT GROUNDBREAKING DISCOVERIES, BUT ALSO TO EXCHANGE IDEAS. THE SYMPOSIUMS WAS HELD THIS YEAR ON SEPTEMBER 21ST AT THE RENEE LUSKIN CENTER AT UCLA. ADVOCACYTHE PMC STRIVES FOR A HEALTHY AMERICA BY ADVOCATING FOR A CARCINOGEN-FREE ENVIRONMENT, INFORMING THE PUBLIC ABOUT THE USE OF ASBESTOS IN AMERICA, AND MOBILIZING THE PUBLIC TO ENSURE ASBESTOS REFORM THROUGH A COMPLETE AND TOTAL BAN. CAREGIVER SUPPORT GROUPTHIS MARKS THE THIRD YEAR SINCE PMC BEGAN OFFERING MONTHLY CAREGIVER SUPPORT GROUP MEETINGS. THE SUPPORT GROUP LED BY PMC NURSE PRACTITIONER LIEN HUA-FENG AND COORDINATED BY CHRISTINA MCSHERRY WAS CREATED TO GIVE CAREGIVERS OF MESOTHELIOMA PATIENTS AN OUTLET TO ASK QUESTIONS, SHARE STORIES, AND RELEASE DIFFICULT EMOTIONS. THE GROUP HELPS CAREGIVERS CONNECT WITH OTHER CARE-GIVERS WHO CAN DIRECTLY RELATE TO THEIR EXPERIENCES.INTERNATIONAL TISSUE BANKTHE PHLBI RECEIVED INSTITUTIONAL REVIEW BOARD (IRB) APPROVAL IN 2016 FOR ITS INTERNATIONAL TISSUE BANK. DISEASES OF THE HEART, LUNG AND BLOOD AFFECT A LARGE NUMBER OF PEOPLE IN THE U.S. AND THROUGHOUT THE WORLD EACH YEAR. IT IS IMPERATIVE THAT BOTH PERSONAL HEALTH INFORMATION AND TISSUE SAMPLES ARE COLLECTED FROM AS MANY PATIENTS AS POSSIBLE IN ORDER TO UNDERSTAND: O THE NORMAL TISSUE BIOLOGY O THE NATURAL HISTORY OF THE DISEASE O OUTCOMES FROM CURRENT TREATMENTS O THE ADVANTAGES AND DISADVANTAGES OF POTENTIAL FUTURE NOVEL THERAPIES PHLBI IS SOLICITING TISSUE SPECIMENS AND SEEKS STUDY PARTICIPANTS WHO WISH TO DONATE THEIR TISSUE AND PERSONAL HEALTH INFORMATION FOR CURRENT AND FUTURE RESEARCH AT THE INSTITUTE.STUDENT INTERNSHIP PROGRAMPHLBI PROVIDES UNDERGRADUATE STUDENT INTERNS FROM UCLA EARLY CAREER TRAINING AND MENTORSHIP IN MEDICAL RESEARCH. OUR INTERNS ARE GIVEN HANDS-ON EDUCATIONAL OPPORTUNITIES THAT ARE DIFFICULT TO OBTAIN AT THEIR HOST UNIVERSITIES AS UNDERGRADUATE STUDENTS. UNIVERSITY RESEARCH LABS ARE OFTEN CONSTRAINED BY LIMITED BUDGETS, WHERE RESOURCES ARE TYPICALLY PRIORITIZED FOR POST-DOCTORAL FELLOWS AND GRADUATE STUDENTS PURSUING ADVANCED DEGREES. AT PHLBI, OUR INTERNS HAVE THE UNIQUE OPPORTUNITY TO GAIN REAL-WORLD EXPERIENCE AND FILL MEANINGFUL ROLES IN MEDICAL RESEARCH AT A YOUNG AGE. IN RETURN, PHLBI'S CORE MISSION OF CONDUCTING CANCER IMMUNOTHERAPY RESEARCH BENEFITS FROM THEIR INVOLVEMENT. 8TH INTERNATIONAL SYMPOSIUM ON MALIGNANT PLEURAL MESOTHELIOMATHE 8TH INTERNATIONAL SYMPOSIUM WAS LED BY ROBERT B. CAMERON, MD, FACS, DIRECTOR OF THE UCLA MESOTHELIOMA COMPREHENSIVE RESEARCH PROGRAM AND SENIOR PROFESSOR AT UCLA. THE ROSTER OF DISTINGUISHED INTERNATIONAL FACULTY AT THE SYMPOSIUM INCLUDED KEVIN G. BLYTH, MD, MBCHB, FRCP, UNIVERSITY OF GLASGOW; NICOLAS BOISGERAULT, PHD, CRCINA CANCER RESEARCH CENTER, FRANCE; LISA M. COUSSENS, PHD, OREGON HEALTH AND SCIENCE UNIVERSITY, PORTLAND; MIKIHIRO KOHNO, MD, PHD, UNIVERSITY OF TORONTO, CANADA; MARC LADANYI, MD, MEMORIAL SLOANE KETTERING, NEW YORK; KEVIN LAMOTE, PHD, UNIVERSITY OF ANTWERP, BELGIUM; CHARLES B. SIMONE II, MD, UNIVERSITY OF MARYLAND MEDICAL CENTER, BALTIMORE, MARYLAND; WESLEY WILSON, PHD CANDIDATE, UNIVERSITY OF WESTERN AUSTRALIA PERTH, AUSTRALIA, AS WELL AS LOCAL EXPERTS FROM UCLA. "TOGETHER WE WALK AS ONE," ANNUAL 5K WALK/HIKE FOR MESOTHELIOMATHE 7TH ANNUAL 5K WALK/HIKE FOR MESOTHELIOMA TOOK PLACE ON SUNDAY, OCTOBER 21ST, 2018 AT THE PARAMOUNT RANCH IN AGOURA HILLS. WITH OVER 350 WALKERS, THE EVENT RAISED OVER $143,000 TO FIND BETTER TREATMENTS FOR MALIGNANT PLEURAL MESOTHELIOMA. THE EVENT BROUGHT TOGETHER THIRTY-TWO TEAMS, AS WELL AS SUPPORTING ORGANIZATIONS AND INDIVIDUAL WALKERS, WHO GATHERED AT THE PARK AT 9 A.M. EACH REGISTRANT RECEIVED A COMPLIMENTARY T-SHIRT, FRUIT PRODUCTS GENEROUSLY DONATED BY DOLE, AND SUNSCREEN, BEFORE LEAVING ON THE HIKE.PHLBI HOLIDAY OPEN HOUSE PHLBI HOSTED ITS ANNUAL HOLIDAY OPEN HOUSE ON DECEMBER 12TH, 2018. THE ANNUAL OPEN HOUSE SHOWCASED THE INNOVATIVE RESEARCH CONDUCTED AT PMC AT THEIR IN-HOUSE RESEARCH LABORATORY IN LOS ANGELES. ATTENDEES MET THE PMC RESEARCHERS, LEARNED ABOUT THE EXCITING RESEARCH TAKING PLACE IN THE LAB, ATE DELICIOUS FOOD AND WATCHED STUDENT INTERNS PERFORM LIVE DEMONSTRATIONS.THE PACIFIC HEART, LUNG & BLOOD INSTITUTE THE MISSION OF THE PACIFIC HEART, LUNG & BLOOD INSTITUTE IS TO SERVE AS A CENTER OF CROSS-DISCIPLINARY SCIENTIFIC RESEARCH THAT SIGNIFICANTLY CONTRIBUTES TO DISCOVERIES OF NEW TREATMENTS FOR HEART, LUNG, AND BLOOD DISEASES, AND TO PROVIDE A PLATFORM FOR MEDICAL EDUCATION FOR BOTH CONSUMERS AND PROFESSIONALS THAT IMPROVES ACCESSIBILITY TO EFFECTIVE TREATMENTS OF THESE DISEASES AND ENHANCES PREVENTION OF THESE CONDITIONS IN THE GENERAL POPULATION. THE PACIFIC MESO CENTERMISSION: THE PACIFIC MESO CENTER'S MISSION IS TO BETTER SERVE MESOTHELIOMA PATIENTS THROUGHOUT THE UNITED STATES BY SUPPORTING THE FIRST-OF-ITS-KIND NATIONAL RESEARCH INSTITUTE DESIGNED TO IMPROVE THEIR LONGEVITY AND QUALITY OF LIFE, AND TO DISCOVER INNOVATIVE THERAPIES FOR OF APPROACHING MALIGNANT PLEURAL MESOTHELIOMA (MPM) AS A CHRONIC, TREATABLE DISEASE.
Interesting data from their 2020 990 filing
From their filing, the objective of the non-profit is stated as “The pacific heart, lung & blood institutethe mission of the pacific heart, lung & blood institute is to serve as a center of cross-disciplinary scientific research that significantly contributes to discoveries of new treatments for heart, lung, and blood diseases, and to provide a platform for medical education for both consumers and professionals that improves accessibility to effective treatments of these diseases and enhances prevention of these conditions in the general population. the pacific meso center mission: the pacific meso center's mission is to better serve mesothelioma patients throughout the united states by supporting the first-of-its-kind national research institute designed to improve their longevity and quality of life, and to discover innovative therapies of approaching malignant pleural mesothelioma (mpm) as a chronic, treatable disease.”.
When talking about its functions, they were outlined as: “Scientific research to develop new treatments for heart, lung, and blood diseases”.
- The legally reported state of operation for the non-profit is CA.
- According to the filing, the non-profit's address in 2020 is 10780 SANTA MONICA BLVD NO 101, LOS ANGELES, CA, 90025.
- The non-profit organization as of 2020 has a total of 5 employees reported on their form.
- Is not a private foundation.
- Expenses are between $500,000 and $1,000,000+.
- Revenue is between $500,000 and $1,000,000+.
- Revenue less expenses is -$252,865.
- The organization has 10 independent voting members.
- The organization was formed in 2002.
- The organization pays $637,260 in salary, compensation, and benefits to its employees.
- The organization pays $3,778 in fundraising expenses.